Overview

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and Oklahoma based on the mean change from baseline in Reflective Total Nasal Symptom Scores (TNSS) assessed over 14 days of treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Faes Farma, S.A.

Collaborators:

Allied Research International
Merck Sharp & Dohme Corp.